SCHEMBL1025296

SCHEMBL1025296

Nc1ccc(C(F)(F)F)cc1O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.50
KDM4E B2RXH2 4/20 0.50
HSD17B10 Q99714 2/20 0.50
CYP3A4 P08684 1/20 0.50
ALOX15 P16050 1/20 0.50
HPGD P15428 1/20 0.50
PKM P14618 2/20 0.46
MEN1 O00255 4/20 0.45
KMT2A Q03164 4/20 0.45
GAA P10253 3/20 0.45
MAPT P10636 3/20 0.45
RAB9A P51151 2/20 0.45
TSHR P16473 1/20 0.45
MAPK1 P28482 1/20 0.45
POLB P06746 1/20 0.45
CFTR P13569 1/20 0.44
ALOX5AP P20292 2/20 0.44
FEN1 P39748 2/20 0.44
RECQL P46063 1/20 0.42
NOS3 P29474 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6823132 1.00 ALDH1A1 (0.50) ALDH1A1KDM4EHSD17B10CYP3A4ALOX15
SCHEMBL3947426 0.86 HSD17B10 (0.50) ALDH1A1KDM4EHSD17B10CYP3A4ALOX15
SCHEMBL3897640 0.84 CYP3A4 (0.65) HSD17B10CYP3A4ALOX15KIF11
SCHEMBL23155928 0.83 ALDH1A1 (0.48) ALDH1A1KDM4EHSD17B10CYP3A4ALOX15
SCHEMBL5958751 0.83 HSD17B10 (0.46) ALDH1A1KDM4EHSD17B10CYP3A4ALOX15
SCHEMBL29399630 0.83 ESR1 (0.50) ALDH1A1KDM4EHSD17B10CYP3A4ALOX15
SCHEMBL766058 0.83 ESR1 (0.50) ALDH1A1KDM4EHSD17B10CYP3A4ALOX15
SCHEMBL29412586 0.83 ESR1 (0.50) ALDH1A1KDM4EHSD17B10CYP3A4ALOX15
SCHEMBL1023841 0.82 ALDH1A1 (0.63) ALDH1A1KDM4EHSD17B10ALOX15HPGD
SCHEMBL11371728 0.81 SMN1; SMN2 (0.46) ALDH1A1KDM4EHSD17B10CYP3A4ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 169 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118557555-B Curcumin compound preparation and application thereof in treating MLL-r leukemia 济宁医学院附属医院 2024-12-06 CN claimed
CN-118557555-A Curcumin compound preparation and application thereof in treating MLL-r leukemia 济宁医学院附属医院 2024-08-30 CN claimed
CN-108059600-B Refining method of tetra (dimethylamino) titanium 浙江博瑞电子科技有限公司 2020-04-10 CN claimed
CN-101253169-B Substituted benzimidazoles and processes for their preparation NOVARTIS AG 2011-11-23 CN claimed
CN-101253168-A Substituted benzimidazoles as kinase inhibitors NOVARTIS AG (CH) 2008-08-27 CN claimed
CN-101253169-A Substituted benzimidazoles and processes for their preparation NOVARTIS AG (CH) 2008-08-27 CN claimed
US-7364881-B1 Biological process for the conversion of nitroarenes to ortho-aminophenols using recombinant E. coli strains UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE AIR FORCE (US) 2008-04-29 US claimed
US-12600720-B2 Modulators of the integrated stress response pathway EVOTEC INTERNATIONAL GMBH (DE) 2026-04-14 US disclosed
US-20260022122-A1 NOVEL COMPOUND FOR INHIBITING NAMPT, AND COMPOSITION INCLUDING SAME CHECKMATE THERAPEUTICS INC. (KR) 2026-01-22 US disclosed
EP-4619388-A1 CATHEPSIN L INHIBITORS Biofront Therapeutics (Beijing) Co., Ltd. (CN) 2025-09-24 EP disclosed
EP-4583870-A2 MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER Mito Biopharma, LLC (US) 2025-07-16 EP disclosed
CN-119775261-A Collagen 1 translation inhibitors and methods of use thereof 艾尼莫生物科技公司 2025-04-08 CN disclosed
EP-4487849-A2 MODULATORS OF THE INTEGRATED STRESS RESPONSE PATHWAY Evotec International GmbH (DE) 2025-01-08 EP disclosed
US-5780483-A IL-8 receptor antagonists SMITHKLINE BEECHAM CORPORATION (US) 1998-07-14 US disclosed
EP-0809492-A1 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1997-12-03 EP disclosed
WO-1997029743-A1 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1997-08-21 WO disclosed
WO-1996025157-A1 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1996-08-22 WO disclosed
US-4731450-A Process for perfluoroalkylation of aromatic derivatives RHONE-POULENC SPECIALITES CHIMIQUES (FR) 1988-03-15 US disclosed
US-4263441-A BENZOXAZOLE DERIVATIVES HOECHST AKTIENGESELLSCHAFT (DE) 1981-04-21 US disclosed
EP-0002030-A1 Fluorinated benzazole derivatives, method for their preparation and their use as optical brighteners HOECHST AKTIENGESELLSCHAFT (DE) 1979-05-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12600720-B2 Modulators of the integrated stress response pathway CRHR2, CRHR1, MC2R ALDH1A1 3637/4885KDM4E 4082/4885HSD17B10 2345/4885
US-20260022122-A1 NOVEL COMPOUND FOR INHIBITING NAMPT, AND COMPOSITION INCLUDING SAME NAMPT, NAPRT, NNT ALDH1A1 789/4885KDM4E 2601/4885HSD17B10 473/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.